Literatur
Nach Information von Bayer Pharma
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
red Sorafenib bei Schilddrüsenkarzinom zugelassen. Info Onkol. 17, 53 (2014). https://doi.org/10.1007/s15004-014-0910-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-014-0910-2